Clinical profile and pattern of Henoch-Schönlein purpura in children

Ganesh Shah
Associate Professor, Department of Paediatrics
Patan Academy of Health Sciences, Lalitpur, Nepal

ABSTRACT

Introduction: This study was done to evaluate clinical profile of Henoch-Schönlein purpura (HSP) in children admitted in Patan Hospital.

Methods: The medical records of all the children admitted in children ward with diagnosis of HSP from January 2008 to December 2015 were analysed for clinical presentation, management and outcome.

Results: Of 59 patients, 37 (63%) were boys. The patients’ ages ranged from 15 months to 14 years with a mean of 8.3 years. Approximately, two third cases presented during winter and autumn. Upper respiratory tract infection preceded HSP in 37 and anti streptolysin O titer was positive in 6 of the 13 (46%) children tested at presentation. Skin purpura was seen in 59 (100%), arthritis or arthralgia in 48 (81%), gastrointestinal manifestation in 47 (80%) and renal involvement in 16 (27%). Forty-one (69%) patients received corticosteroid therapy. All the children made a full recovery, two with nephritis continued to have hypertension, hematuria and proteinuria. Symptoms occurred in 6 (10%) over a period one month to two years follow up.

Conclusions: The HSP in children had seasonal occurrence, skin rash, pain abdomen with mild diseases and recovered well.

Keywords: clinical profile, Henoch-Schönlein purpura, vasculitis, palpable purpura
INTRODUCTIONS

Henoch-Schönlein purpura (HSP) is the most common vasculitis of childhood. Approximately 90% of HSP cases occur in children between the ages 3 and 10 year.\(^1\) It is characterized by non-thrombocytopenic purpura, arthritis or arthralgia, abdominal pain, gastrointestinal hemorrhage and renal manifestations.\(^2\) The classical triad seen is palpable purpura, abdominal colicky by pain or hemorrhage and joint pain. However, diagnostic confusion can arise in cases who present with absence of cutaneous features.\(^3\) This study evaluates the clinical profile of HSP in children admitted in Patan Hospital.

METHODOLOGY

The medical records of all the children admitted in children ward with diagnosis of HSP from January 2008 to December 2015 were retrieved and analyzed. Diagnosis of HSP was based on presence of at least two of the following four criteria: 1) Palpable purpura not related to thrombocytopenia, 2) Age 20 years or younger at onset, 3) Bowel angina, 4) Histological changes showing granulocytes in the walls of arterioles or venules.\(^4\) The demography (age and gender) and clinical characteristics, laboratory data at onset, therapy, and recurrence were studied. Renal biopsies done were graded according to the classification of the International Study of Kidney Disease in children (ISKDC).\(^5\)

Recurrences were defined as a new flare-up of skin rash or other systemic complications following resolution of the disease for at least one month.\(^6\) Continuous variables (such as age) were expressed as mean, median, and range. Absolute numbers as well as percentages were presented for the study variables. Descriptive analysis was done.

RESULTS

There were total of 59 (m 37, f 22) children with HSP. All patients had non-thrombocytopenic palpable purpura, distributed mainly over the legs, buttocks, and upper extremities, (Table 1, 2).
Prednisolone 1-2 mg/Kg/day was prescribed to 41/59 (69%) patients for renal involvement, or joint and GI manifestations. All patients made a full recovery. Two and persistent proteinuria were on regular follow up.

The C-reactive protein, elevation of ESR and leucocytosis were seen in children with HSP, (Table 3).

<table>
<thead>
<tr>
<th>Laboratory Test</th>
<th>Positive/Tested n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leukocytosis (WBC &gt; 11000/mm$^3$)</td>
<td>28/59 (47.4)</td>
</tr>
<tr>
<td>Thrombocytosis (platelets &gt; 500000 cell/mm$^3$)</td>
<td>14/59 (23.7)</td>
</tr>
<tr>
<td>Anemia (Hemoglobin &lt; 11 gm/dl)</td>
<td>9/46 (19.5)</td>
</tr>
<tr>
<td>Elevated ESR</td>
<td>20/39 (51.2)</td>
</tr>
<tr>
<td>Positive ASO titer (&gt; 200 IU/ml)</td>
<td>6/13 (46)</td>
</tr>
<tr>
<td>Increased C-reactive protein</td>
<td>12/21 (57.1)</td>
</tr>
<tr>
<td>Positive throat culture</td>
<td>0/19 (0)</td>
</tr>
<tr>
<td>Low C3</td>
<td>3/13 (23)</td>
</tr>
<tr>
<td>Renal Biopsy</td>
<td>2/2 (100)</td>
</tr>
</tbody>
</table>

Table 3. Laboratory findings among HSP patients

DISCUSSIONS

In the present study, nearly 75% of children were less than 10 years of age. Male to female ratio was 1.68:1. Similar results were obtained by Cakir Murat et al. in their study of 116 children, 73 (63%) were male and 43 (37%) females with a ratio of 1.69:1. Naveed Shahzad et al. in their 27 patients, 17 (63%) males and 10 (37%) females with a ratio of 1.7:1 and a slight female preponderance was found in some studies. Henoch-Schönlein purpura occurs throughout the year, but a number of studies have noted seasonal variation, with most patients presenting from fall through spring and a paucity of cases in the summer months. In the current study, there were more patient in winter and fall (66%). Mahar Khadar et al. found distribution of admission was highest in winter months. Nearly 56% of patients had a potential trigger event before HSP onset, which is consistent with study done by Amer A Lardhi in 2012 found potential trigger event before HSP onset in 55% of cases.

The main clinical features of HSP included purpuric rash, GI symptoms, joint and kidney manifestations. Classic skin purpura was present in all the patients in current study. Similar results were observed by I Kumar et al. Rashes were often seen in the lower extremities and buttocks, but some also had involvement of the arms and face. Joint involvement including arthritis and arthralgia is common, occurring in up to 75% of the children with HSP, with a predilection for the lower extremities. It was observed in 81% of the patients in our study and mainly affecting ankles and knees. The joints of the upper extremities were involved in few patients.

Gastrointestinal manifestations of HSP occur in up to 80% of children with HSP and include abdominal pain, vomiting, diarrhea and melena; intussusception, mesenteric ischaemia and intestinal perforation are uncommon. Gastrointestinal manifestation has been described in up to 75% in some series. Abdominal pain was present in 66.6% of cases reported by Naveed Shahzad et al. in May 2015. Whereas Saulsbury FT found that abdominal pain was present in 63% of patients. Abdominal colic, vomiting and gross or occult bleeding are the dominant features of GI involvement; 46 (80%) patients in our study. None of the patients developed intussusception or perforation in the current study.

The long term morbidity and mortality of HSP are related to the severity of renal involvement. The reported incidence of renal involvement varies from 10-50%; with end stage renal disease in 5%. In the present study, renal involvement occurred in 16 (27.0%) patients. Amer A. Lardhi found renal involvement in 19 out of 78 (24%) patients.

The low incidence of renal involvement in the current series may be related to local variations in causative and environmental factors. The main clinical features of renal involvement in the present study were microscopic hematuria with or without proteinuria, and nephrotic syndrome.
Nephritic syndrome developed in 5 (31%) patients. The overall outcome of HSP nephritis is good. All patients with nephritis in the present study made a complete recovery, but two patients who had hypertension, hematuria and persistent proteinuria required treatment for hypertension and were on regular follow up.

Other less common potential manifestations of HSP are orchitis, carditis, inflammatory eye disease, testicular torsion, and pulmonary hemorrhage, which were not present in our study. Seizure are rare manifestations of CNS involvement in patients with HSP. Two patients (3.3%) developed seizure because of hypertensive encephalopathy in this study, which is also consistent with study done by Amer A. Lardhi who found seizure in 2.5% of cases.

In agreement with literatures, the present data show increased ESR in 20/39 (51%), CRP in 12/21 (57%), leukocytosis in 28/59 (47%), Table 3. Complement component were decreased in 3/13 (23%). Decreased complement levels are reported in 10-18% and increased serum IgA in 0-62% but are not routinely measured.

The frequency of relapses varies from 5-66%. In the present study, 6 (10%) patients relapsed within the first 2 years. These figures are similar to Amer A. Lardhi who found 8% relapse in his patients within the first 2 years.

Some of the patients with HSP require only supportive measures. Corticosteroid therapy reduces the duration and severity of abdominal and joint pain, but corticosteroids do not prevent the development of nephritis, or alter the natural course of HSP. However, 41 (69%) patients in the present study received steroid for GI and renal involvement. Patients with severe HSP nephritis may require other regimen of treatment. This may include high dose steroid, azathioprine, cyclophosphamide, mycophenolate mofetil, intravenous immunoglobulin and plasma pheresis.

In this study, we did not include all cases attended the outpatient departments in pediatrics and dermatology. Therefore, these cases might represent the severe form of clinical presentations only.

CONCLUSIONS

The HSP in children had seasonal occurrence, skin rash, pain abdomen with mild disease and recovered well.

REFERENCES


